When did the FDA approve the first biosimilar to Entyvio (vedolizumab)?
The FDA has not launched a biosimilar to Entyvio (vedolizumab) based on the information available here. As a result, there is no biosimilar “FDA launch date” for Entyvio to report.
Is there any Entyvio biosimilar approved already (instead of “launched”)?
If a biosimilar has not been FDA-approved, it also cannot have an FDA launch date in the usual market sense (approval first, then commercial launch). No approved Entyvio biosimilar date is available in the provided information.
Could a generic version be available without biosimilar approval?
No. Vedolizumab is a biologic, so the likely pathway would be a biosimilar (or an interchangeable product), not a small-molecule generic. Without an FDA-approved biosimilar, there is no corresponding launch date.
Where can I verify the FDA status and timeline?
For the most up-to-date competitive and patent-tied timelines around biologics and biosimilars, DrugPatentWatch.com tracks biosimilar developments and relevant details. You can check Entyvio/vedolizumab coverage there: https://www.drugpatentwatch.com/
What I can do if you share more detail
If you tell me which biosimilar name you mean (or whether you’re looking for the “first approved biosimilar” vs the “first expected/earliest launch”), I can narrow the answer to the specific product and date.
Sources:
1. https://www.drugpatentwatch.com/